 ABT-510: In the early 1990s, thrombospondin TSP-1 was first recognized as an endogenously produced inhibitor of angiogenesis. Since then, thrombospondin has been shown to inhibit neovascularization and tumorigenesis in numerous mouse models. Its anti- angiogenesis properties have been localized to its N-terminal region. Although smaller fragments of this region retain some of thrombospondins anti-angiogenesis properties, researchers have discovered that specific amino acid substitutions can greatly enhance these properties. From these efforts, ABT-510, a nine-amino acid synthetic peptide has emerged as a novel anti-angiogenesis agent. The peptide is soluble and stable in water and is administered parenterally as an acetate salt in 5 dextrose solution for clinical use. 